Synergistic Effects of Targeting Survivin and CDK1 on Nasopharyngeal Carcinoma <i>in Vitro</i> and <i>in Vivo</i>
- 1 Department of Medical Examination, Hainan Provincial People’s Hospital, Haikou, China
- 2 Key Laboratory for Cell and Molecular Genetic Translational Medicine of Hainan Province, Haikou, China
- 3 Key Laboratory for Cell and Molecular Genetic Translational Medicine of Hainan Province, Haikou, China
- 4 Key Laboratory for Cell and Molecular Genetic Translational Medicine of Hainan Province, Haikou, China
- 5 Key Laboratory for Cell and Molecular Genetic Translational Medicine of Hainan Province, Haikou, China
- 6 Key Laboratory for Cell and Molecular Genetic Translational Medicine of Hainan Province, Haikou, China
Abstract
Background: To explore the impact of pU6-based tandem survivin and CDK1-specific short hairpin RNA on the biological behaviors of CNE-2 nasopharyngeal carcinoma cells in vitro and in vivo . Patients and Methods: The vectors of pU6-survivin shRNA , pU6-CDK1 shRNA and pU6-survivin shRNA -CDK1 shRNA were constructed and transfected into CNE-2 cells with Lipofectamine TM 2000, respectively. The mRNAs and proteins of CDK1 and survivin were determined by RT-PCR and Western blotting, accordingly. MTT assay was employed to evaluate the proliferation of CNE-2 cells, and flow cytometry was performed to determine the apoptosis of CNE-2 cells. The effects of interfering survivin and CDK1 on tumorigenesis were evaluated by tumor xenografts experiments. Results: Effective plasmids were successfully constructed knocking down survivin and/or CDK1. The proliferation inhibition of CNE-2 cells by pU6-survivin shRNA -CDK1 shRNA (32.5%) was higher than that of by pU6-survivin shRNA (25.6%) and pU6-CDK1 shRNA (15.6%) , and apoptosis in CNE-2 cells simultaneously interfering survivin and CDK1 (15.2%) dramatically increased when compared to those of interfering survivin (5.4%) or CDK1 (4.7%) alone. Furthermore, simultaneously interfering survivin and CDK1 is more effective than interfering alone component in inhibiting tumor growth of fBalb/C nude mice xenografted with CNE-2 cells. Conclusion: The results altogether indicate that interfering survivin and CDK1simutaneously can produce synergistic effects of anti-nasopharyngeal carcinoma, which could be a potential therapeutic method.
- Yu, M.C. and Yuan, J.M. (2002) Epidemiology of Nasopharyngeal Carcinoma. Seminars in Cancer Biology, 12, 421-429. https://doi.org/10.1016/S1044579X02000858
- Altier, D.C. (2003) Survivin, Versatile Modulation of Cell Division and Apoptosis in Cancer. Oncogene, 22, 8581-8589. https://doi.org/10.1038/sj.onc.1207113
- Altieri, D.C. (2008) Survivin, Cancer Networks and Pathway-Directed Drug Discovery. Nature Reviews Cancer, 8, 61-70. https://doi.org/10.1038/nrc2293
- Mita, A.C., Mita, M.M., Nawrocki, S.T. and Giles, F.J. (2008) Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics. Clinical Cancer Research, 14, 500-505. https://doi.org/10.1158/1078-0432.CCR-08-0746
- Chiou, S.K., Jones, M.K. and Tarnawski, A.S. (2003) Survivin an Anti-Apoptosis Protein: Its Biological Roles and Implications for Cancer and Beyond. Medical Science Monitor, 9, PI25-9.
- Altieri, D.C. (2003) Validating Survivin as a Cancer Therapeutic Target. Nature Reviews Cancer, 3, 46-54. https://doi.org/10.1038/nrc968
- Moseley, J.B. and Nurse, P. (2009) Cdk1 and Cell Morphology: Connections and Directions. Current Opinion in Cell Biology, 21, 82-88. https://doi.org/10.1016/j.ceb.2008.12.005
- Salaun, P., Rannou, Y. and Prigent, C. (2008) Cdk1, Plks, Auroras, and Neks: The Mitotic Bodyguards. Advances in Experimental Medicine and Biology, 617, 41-56. https://doi.org/10.1007/978-0-387-69080-3_4
- Barrett, R.M., Osborne, T.P. and Wheatley, S.P. (2009) Phosphorylation of Survivin at Threonine 34 Inhibits Its Mitotic Function and Enhances Its Cytoprotective Activity. Cell Cycle, 8, 278-283. https://doi.org/10.4161/cc.8.2.7587
- Xi, Q.H., Huang, M.H., Wang, Y.Y., Zhong, J.X., Liu, R., Xu, G.Q., et al. (2015) The Expression of CDK1 Is Associated with Proliferation and Can Be a Prognostic Factor in Epithelial Ovarian Cancer. Tumor Biology, 36, 4939-4948. https://doi.org/10.1007/s13277-015-3141-8
- Hongo, F., Takaha, N., Oishi, M., Ueda, T., Nakamura, T., Naitoh, Y., et al. (2014) CDK1 and CDK2 Activity Is a Strong Predictor of Renal Cell Carcinoma Recurrence. Urologic Oncology, 32, 1240-1246. https://doi.org/10.1016/j.urolonc.2014.05.006
- Goga, A., Yang, D., Tward, A.D., Morgan, D.O., Bishop, J.M., et al. (2007) Inhibition of CDK1 as a Potential Therapy for Tumors Over-Expressing MYC. Nature Medicine, 13, 820-827. https://doi.org/10.1038/nm1606